

Fig. 1 Bis In<sup>3+</sup> IMP 274





Fig. 2 Bis In<sup>3+</sup> IMP 274 (SN-38 analog)



**Fig. 3 Bis In<sup>3+</sup> IMP 274 (SN-38 analog with penicillamine linker)**




Fig. 4 Bis In<sup>3+</sup> IMP 274 (SN-38 analog linked to a cysteine using a hindered ester)




Fig. 5 IMP 225




Fig. 6 Bis In<sup>3+</sup> IMP 224




Fig. 7 HPLC analysis (Reverse Phase) of  $^{111}\text{In}$ -Labeled IMP 274




Fig. 8 HPLC Analysis (Size Exclusion) of  $^{111}\text{In}$ -Labeled IMP 274






Fig. 9A     HPLC analysis (Reverse Phase) of  
 $^{111}\text{In}$ -Labeled IMP 274 in Mouse Serum

CHANNEL A   INJECT   04/17/02 13:31:56   STORED TO BIN # 6

t = 0 hrs

8.76  
8.29 7.92

ER 0  
DATA SAVED TO BIN # 6

CHANNEL A   INJECT   04/17/02 14:08:49   STORED TO BIN # 8

t = 0.5 hrs

8.80  
8.28 8.01

ER 0  
DATA SAVED TO BIN # 8

CHANNEL A   INJECT   04/17/02 14:29:52   STORED TO BIN # 9

t = 1 hrs

8.84  
8.04

ER 0  
DATA SAVED TO BIN # 9

CHANNEL A   INJECT   04/17/02 15:29:20   STORED TO BIN # 11

t = 2 hrs

8.75  
7.59

ER 0  
DATA SAVED TO BIN # 11

Fig. 9B     HPLC analysis (Reverse Phase) of  
 $^{111}\text{In}$ -Labeled IMP 274 in Mouse Serum




Fig. 10A HPLC analysis (Reverse Phase) of  
 $^{111}\text{In}$ -Labeled IMP 274 in Human Serum




Fig. 10B    HPLC analysis (Reverse Phase) of  
 $^{111}\text{In}$ -Labeled IMP 274 in Human Serum




Fig. 11     HPLC analysis (Size Exclusion) of  $^{111}\text{In}$ -Labeled IMP 274 in  
Mouse Serum containing bsAb 734xhMN14




Fig. 12     HPLC analysis (Size Exclusion) of  $^{111}\text{In}$ -Labeled IMP 274 in Human Serum containing bsAb 734xhMN14





Fig. 13     Stability of IMP 294 (A) and IMP 295 (B) in PBS at 25°C  
Over 7 Days

---

A



B




Fig. 14 Pre-targeting in SCID Mice

A.

SCID Mice Inoculated i.v. with $1.5 \times 10^7$ Daudi Cells					
Group	(N)	Treatment	Ratio	Dose	Schedule
I	9	LL2x734 IMP-225	(1:1)	300 $\mu\text{g}$ ( $3 \times 10^{-9}$ moles) ~ 6 $\mu\text{g}$ ( $3 \times 10^{-9}$ moles)	Days 1, 3, 7, 9 Days 2, 4, 8, 10
II	8	IMP-225 Alone	N/A	~ 30 $\mu\text{g}$ ( $1.5 \times 10^{-8}$ moles)	Days 2, 4, 8, 10

B.






Fig. 15     Synthesis of DTPA Precursor and DTPA (Three Step Method)




Fig. 16     Synthesis of DTPA Precursor and DTPA (Four Step Method)

